Spontaneous coronary artery dissection.

Spontaneous coronary artery dissection (SCAD) is a rare and potentially deadly disease without a clear and universal treatment. Medical as well as mechanical interventions, including percutaneous and coronary bypass surgery, have been used. We present two dissimilar cases of SCAD that required markedly different treatments reflecting the variety in clinical presentation and outcome. A brief review of the literature is included.

Simple method for evaluating cardiac output.

This study compared the accuracy of a formula calculating cardiac output utilizing a patient size modification of a pulse pressure formula of Starr with that measured with a standard thermal dilution technique. During a six-month period 111 patients in the intensive care unit (ICU) on the cardiothoracic and vascular surgical services had comparison of their cardiac output by these two methods. The basic formula of Starr for stroke volume was converted to a stroke volume index by dividing by 1.7 and the empirically derived average body surface area in meters square. The stroke volume index was multiplied by the body surface area (BSA) of the patient to determine the patient's stroke volume in ml. Thus the modified stroke volume formula was 100-0.6 age-0.6 Diastolic Pressure + 0.5 Pulse Pressure x Patients BSA (m2)" over 1.7. Cardiac output was calculated by multiplying the stroke volume by heart rate. Nearly 60% of the patients had less than a 5% difference between the two methods, and over 90% had less than a 10% variance. In this particular population the highest variation was 18%. Thus, using only a carefully measured sphygmomanometer blood pressure, stroke volume and cardiac output can be determined with sufficient accuracy for clinical use.

When things go wrong: the impact of being a statistical outlier in publicly reported coronary artery bypass graft surgery mortality data.

The public reporting of hospital quality and safety data is a growing phenomenon. Yet there are few reports of the effects of publicly reported data on individual organizations, particularly when the data show worse than expected performance. In this article, our hospital's response to having a mortality rate from coronary artery bypass graft surgery that was significantly higher than other programs in the Commonwealth of Massachusetts is reported. The data caused suspension of elective cardiac surgery at the institution, and an independent review of the program was undertaken. The effects of the suspension and publication of mortality data on quality and patient safety, the residency training program in cardiothoracic surgery, and the financial performance of the hospital are described. Several lessons were learned that may be of value to other health care organizations that experience a public crisis in clinical quality.

Intraoperative detection of a bronchial carcinoid with a radiolabeled somatostatin analog.

Carcinoid tumors of the lung are rare neuroendocrine tumors that make up approximately 1 to 2% of all lung neoplasms. These tumors overexpress somatostatin receptors, and somatostatin analog therapy has become standard in the treatment of carcinoid tumors. In addition, radiolabeled somatostatin analogs have been used to diagnose and treat these lesions. We describe the case of a patient with a right lung mass diagnosed as a carcinoid tumor. The patient underwent complete resection of this tumor with the assistance of intraoperative detection with a handheld gamma probe after the administration of the radiolabeled somatostatin analog (111)In-pentetreotide. This approach allowed us not only to detect the tumor easily, but to scan the bed of the tumor after resection and to re-excise an area of increased radioisotope uptake that corresponded to the presence of residual tumor. We believe this to be the first reported case of bronchial carcinoid resected with the assistance of intraoperative gamma detection after the administration of a radiolabeled somatostatin analog. This technology allowed us to achieve a complete surgical resection with no residual tumor detected either pathologically or by somatostatin scanning.

Findlay Implantable Two-Stage Centrifugal Pump.

The Findlay centrifugal pump is unique in its two-stage pumping mechanisms and in its complementary interrelationship of the stages to each other and to the exit system, and it forms an extremely efficient unit. The first stage is a lift force pump as an inlet. The second and major stage is a shear force pump. Twenty-six prototypes, many multiply modified, have been hand fabricated, and most have had classic pump function analyses. Six pumps have demonstrated minimal hemolysis (3.5-5 h). At modest rotation speeds, it pumps water up to 10 L/min. Forty-four acute studies in normal dogs have been performed with the Findlay pump in a ventricular assist system. Blood flows through the pump ranged from 1.2 to 4.5 L/min. The conclusion is that the Findlay pump has the ability to operate with low blood damage, performs at acceptable rotational speed with reasonable hydraulic and mechanical efficiency, and is small and implantable.

Partial anomalous pulmonary venous connection in adults: a simplified approach.

Partial anomalous pulmonary venous connection with infradiaphragmatic drainage into the inferior vena cava (scimitar syndrome) constitutes a rare diagnosis in adults. Diagnosis is suggested by plain chest roentgenogram and confirmed by computed tomography angiography or magnetic resonance imaging. Reported operations for scimitar syndrome are complex, often requiring circulatory arrest. Reoperation for pulmonary vein stenosis is a troubling complication. We report an effective simplified operation for use in adults.

NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus).

Neuroendocrine tumors (NETs) of the thorax, including bronchial and thymic neuroendocrine NETs, are often referred to as NETs of the foregut. The incidence and prevalence of NETs are increasing in the United States as demonstrated in the Surveillance, Epidemiology, and End Results from 1973 to 2004 (J Clin Oncol. 2008;26[18]:3063-3072). Although the majority of bronchial and thymic NETs are sporadic, approximately 5% to 10% can be associated with hereditary syndrome, multiple endocrine neoplasms type 1 (Nat Rev Cancer. 2005;5[5]:367-375). Diagnosis is made by tissue pathology, allowing for characterization and classification of the NET. Radiologic evaluation is performed to determine the extent of disease involvement. Clinical symptoms from hormonal overproduction or from paraneoplastic processes are medically managed to improve patients' quality of life. Locoregional disease can be curative with surgery; however, distant or metastatic disease is rarely curable. Therapeutic options for metastatic/advanced NETs of the thorax are mainly to palliate symptoms. Final treatment recommendations for patients with either bronchial or thymic NETs should be individualized, weighing the risks and benefits of therapy.

Pancreatic resection: a key component to reducing racial disparities in pancreatic adenocarcinoma.

BACKGROUND: Blacks are affected disproportionately by pancreatic adenocarcinoma and have been linked with poor survival. Surgical resection remains the only potential curative option. If surgical disparities exist, then they may provide insight into outcome discrepancies. METHODS: Patients with pancreatic adenocarcinoma were identified using the National Cancer Institute's Surveillance, Epidemiology, and End Results data from 1992 to 2002. Univariate analyses were used to compare demographics, tumor characteristics, and surgical data; and logistic regression was used to determine independent predictors for recommendation/performance of surgery. Kaplan-Meier survival was assessed, and a Cox proportional hazards model was used to examine adjusted predictors of survival. RESULTS: In total, 27,828 patients were identified; 81.4% were white, 11.5% were black, 7.2% were of other race. White patients and black patients presented with similar stage and had surgery recommended at similar rates (34.5% vs 34%, respectively; P = .57). Black patients underwent fewer resections (10.6% vs 12.7%; P < .001). Multivariate analysis confirmed that black patients were less likely to undergo resection (adjusted odds ratio, 0.69; 95% confidence interval [95% CI], 0.57-0.84). Overall, black patients had worse univariate survival. The survival among black patients who underwent resection did not differ statistically from the survival of similar white patients, although the median survival trended lower (11 months vs 13 months; P = .13). In a multivariate Cox model, black race predicted worse survival (hazards ratio, 1.11; 95% CI, 1.07-1.16), and pancreatic resection was protective (hazards ratio, 0.56; 95% CI, 0.53-0.59). CONCLUSIONS: Black and white patients with pancreatic adenocarcinoma presented with similar stages and were recommended for pancreatectomy at similar rates, yet black patients underwent fewer resections. After resection, crude survival did not differ significantly between white and black patients, although multivariate analysis demonstrated a survival disadvantage for blacks despite adjusting for resection. The current results suggested that pancreatectomy may be underused for blacks. Maximizing resection rates for appropriate patients may be an important component in reducing outcome disparities for pancreatic adenocarcinoma.

Development of a human cardiac tissue-based angiogenesis model.

BACKGROUND: Previous angiogenesis models use animal tissues such as the chicken chorioallantoic membrane (CAM) or the rabbit cornea. These models may not accurately reflect the mechanisms responsible for human angiogenesis. MATERIALS AND METHODS: We hypothesized that fragments of human myocardial tissue would develop an angiogenic response from the cut edges of vessels contained within the tissue. To test these hypotheses, we obtained human atrial appendage tissue at the time of cardiac bypass. Fragments of atrial tissue were then incorporated into fibrin thrombin clots. Tissue fragments were observed, and the percent of wells that developed neovessel invasion into the clot was calculated (%I). The subsequent growth of cardiac-derived microvessels was rated and scored over time (Angiogenic Index). RESULTS: There were 20 human atrial appendages plated (n = 24 to 60 wells/specimen) and evaluated in this model. Out of the 20, 16 (80%) atrial appendages developed an angiogenic response in the majority (>50%) of wells plated. Neovessel growth was progressive over 14 to 16 days in culture in all specimens tested. The mean angiogenic index of all specimens was 8.59 +/- 0.91. CONCLUSIONS: This human cardiac tissue-based assay might be useful to screen compounds designed for use in human trials or provide highly vascularized cardiac tissue for autotransplantation. Additionally, the assay provides the foundation to study an individual patent's cardiac tissue and its response to angiogenesis stimulators or inhibitors. This may allow the development of patient-specific therapies designed to enhance revascularization or repair of injured cardiac muscle.

Development of a novel in vitro human tissue-based angiogenesis assay to evaluate the effect of antiangiogenic drugs.

OBJECTIVE: To describe a novel in vitro human tissue-based angiogenic model that can predict an individual tumor's response to antiangiogenic drugs. SUMMARY BACKGROUND DATA: A number of in vitro and in vivo angiogenesis assays exist, but they do not provide potentially useful information for the treatment of an individual patient. Clonogenic assays have been used to evaluate the response of an individual's tumor to antineoplastic agents, but these tumor fragments are cultured in an environment that does not lead to neovessel growth. The authors have previously demonstrated that human vein disks or human tumor xenograft fragments incorporated into a 0.3% fibrin-thrombin clot will develop angiogenic vessel growth from the cut edge of the vessel disk or xenograft fragment. METHODS: Fresh human tumor or normal tissue disks (2 x 1 mm) from fresh surgical specimens were incorporated into fibrin-thrombin clots overlain with nutrient medium containing either 20% fetal bovine serum alone or in combination with Epothilone B, a tubulin inhibitor with antiangiogenic properties. Tissue disks were visually assessed over time to determine the percentage of wells that developed an angiogenic response. Neovessel growth, density, and length were graded at intervals using a semiquantitative visual neovessel growth-rating scheme (angiogenic index, 0-16 scale) devised in the authors' laboratory. RESULTS: Epothilone B treatment at doses of 10-6 mol/L and 10-8 mol/L decreased the number of wells that developed an invasive angiogenic response and limited the development of vessels that invaded the matrix. At these doses, Epothilone B also caused regression of vessels in wells that had been allowed to develop an angiogenic response. Treatment of tumors or normal tissues with Epothilone B at doses less than 10-8 mol/L was ineffective. CONCLUSIONS: Epothilone B may be an effective antiangiogenic agent in a variety of tumor types. The authors speculate that this in vitro model might provide useful information to the clinician on the effect of specific antiangiogenic agents on individual tumors. This may be particularly useful in patients with tumors that, as a group, are unresponsive to treatment with antineoplastic agents.